vTv Therapeutics Inc
VTVT14.730USD
+0.155+1.06%
取引時間 （ET）15分遅れの株価
38.48M時価総額
損失額直近12ヶ月PER
詳細情報 vTv Therapeutics Inc 企業名
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.
企業情報
企業コードVTVT
会社名vTv Therapeutics Inc
上場日Jul 30, 2015
最高経営責任者「CEO」Mr. Paul Jai Sekhri
従業員数23
証券種類Ordinary Share
決算期末Jul 30
本社所在地3980 Premier Dr
都市HIGH POINT
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号27265
電話番号13368410300
ウェブサイトhttps://vtvtherapeutics.com/
企業コードVTVT
上場日Jul 30, 2015
最高経営責任者「CEO」Mr. Paul Jai Sekhri
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-82.80%
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
2.25K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
--
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Dr. Michael Tung, M.D.
Dr. Michael Tung, M.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
--
--
Dan Spiegelman
Dan Spiegelman
Director
Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-82.80%
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
2.25K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
--
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
収益内訳
FY2023
データなし
地域別USD
会社名
収益
比率
United States
0.00
0.00%
事業別
地域別
データなし
株主
更新時刻: Fri, May 16
更新時刻: Fri, May 16
株主統計
種類
株主統計
株主統計
比率
MacAndrews & Forbes Holdings, Inc.
34.88%
Samsara BioCapital, LLC
7.90%
Fidelity Management & Research Company LLC
6.81%
Baker Bros. Advisors LP
3.72%
The Vanguard Group, Inc.
1.59%
Other
45.10%
株主統計
株主統計
比率
MacAndrews & Forbes Holdings, Inc.
34.88%
Samsara BioCapital, LLC
7.90%
Fidelity Management & Research Company LLC
6.81%
Baker Bros. Advisors LP
3.72%
The Vanguard Group, Inc.
1.59%
Other
45.10%
種類
株主統計
比率
Holding Company
34.88%
Investment Advisor
8.96%
Venture Capital
7.90%
Hedge Fund
4.09%
Investment Advisor/Hedge Fund
1.09%
Individual Investor
0.72%
Other
42.35%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
54
1.51M
57.65%
-16.72K
2025Q1
53
1.53M
60.03%
+1.63K
2024Q4
55
1.51M
61.92%
-7.51K
2024Q3
55
1.49M
61.31%
+181.69K
2024Q2
53
1.29M
53.13%
+308.00
2024Q1
64
1.68M
72.07%
+129.32K
2023Q4
64
1.40M
68.78%
-52.49K
2023Q3
72
1.41M
69.35%
-49.61K
2023Q2
81
1.40M
81.32%
+323.67K
2023Q1
107
1.40M
81.41%
+294.71K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
MacAndrews & Forbes Holdings, Inc.
912.98K
34.88%
--
--
Apr 01, 2025
Samsara BioCapital, LLC
206.78K
7.9%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
178.20K
6.81%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
97.31K
3.72%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
41.56K
1.59%
--
--
Mar 31, 2025
Northern Trust Investments, Inc.
15.63K
0.6%
+15.63K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
12.64K
0.48%
+1.00K
+8.62%
Mar 31, 2025
Connective Capital Management, LLC
9.38K
0.36%
+9.38K
--
Mar 31, 2025
Sekhri (Paul Jai)
5.00K
0.19%
-24.06K
-82.80%
Apr 01, 2025
Northern Trust Global Investments
4.71K
0.18%
-194.00
-3.96%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
比率0.01%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
日付
種類
比率
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
